Seraxis

Seraxis is a private, clinical-stage biotech focused on a stem cell-derived islet replacement therapy for Type 1 Diabetes. Its core technology is based on a proprietary, engineered stem cell line designed to produce pure, potent, and immunologically compatible pancreatic endocrine cells. The company is advancing its lead program toward clinical trials and is actively seeking strategic partnerships to accelerate development and broaden the application of its platform.

Proprietary stem cell line engineered from a donor's pancreatic islet, differentiated into pancreatic endocrine cell clusters for transplantation. Platform focuses on purity, allogeneic compatibility, and genetic modifications for future immune evasion.

Seraxis competes in a crowded field with companies like Vertex Pharmaceuticals (VIA-809 program), Sernova Corp (Cell Pouch System), and others developing stem cell-derived islet replacement therapies. Differentiation hinges on its proprietary cell line origin, claims of enhanced compatibility, and its roadmap toward an immune-evasive product.